Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
610
Trial Sponsor
Clinical Trial Start Date
March 22, 2021
0Primary Completion Date
October 20, 2022
0Study Completion Date
October 20, 2022
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Biological0
Intervention Name
Posoleucel (formerly known as ALVR105) cells0
Placebo (visually identical to Posoleucel)0
Interventional Trial Phase
Phase 20
Participating Facility
Official Name
Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Dosing Interval, 2-period Study of the Safety, Tolerability and Effectiveness of Adoptively Transferred Posoleuccel (ALVR105) Multivirus-specific T Cells in Kidney Transplant Recipients With Either High or Low Levels of BK Viremia0
Last Updated
July 11, 2023
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Quadruple0
Masked Party
Outcomes Assessor0
Participant0
Care Provider0
Investigator0
Study summary
The purpose of this study is to compare Posoleucel (formerly known as ALVR105; Viralym-M) to placebo in kidney transplant recipients who have high or low levels of BK virus in their blood.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
